 CBR by Generate Life Sciences, the worlds largest private newborn stem cell bank, and NantKwest Nasdaq: NK, a clinical-stage, natural killer cell-based immunotherapy company, today announced a collaboration to develop a COVID-19 treatment leveraging newborn stem cells. CBR will provide research-donated umbilical cord tissue-derived mesenchymal stem cells MSCs to NantKwest for efficient and robust expansion utilizing their proprietary modular, closed bioreactor system from NantKwest affiliate ImmunityBio, Inc. 